SCHEMBL9910945

SCHEMBL9910945

Cc1cccnc1Oc1ccc(Cl)cc1

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 2/20 0.56
L3MBTL1 Q9Y468 6/20 0.53
HTT P42858 2/20 0.53
NPSR1 Q6W5P4 1/20 0.53
KMT2A Q03164 4/20 0.52
POLB P06746 4/20 0.52
KDM4E B2RXH2 4/20 0.52
ALDH1A1 P00352 3/20 0.52
MEN1 O00255 3/20 0.47
MAPK1 P28482 2/20 0.47
MAPT P10636 2/20 0.46
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2C9 P11712 1/20 0.46
HPGD P15428 1/20 0.46
CYP2C19 P33261 1/20 0.46
P2RX3 P56373 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8467578 0.85 KMT2A (0.63) RAB9AL3MBTL1HTTNPSR1KMT2A
SCHEMBL3660640 0.83 TDP1 (0.54) L3MBTL1HTTNPSR1KMT2AALDH1A1
SCHEMBL2460533 0.82 KMT2A (0.56) RAB9AL3MBTL1HTTNPSR1KMT2A
SCHEMBL13680418 0.82 KMT2A (0.47) NPSR1KMT2AKDM4EALDH1A1MEN1
SCHEMBL29716346 0.81 KMT2A (0.45) L3MBTL1HTTNPSR1KMT2APOLB
SCHEMBL22061929 0.81 KMT2A (0.45) L3MBTL1HTTNPSR1KMT2APOLB
SCHEMBL12925927 0.81 KDM4E (0.47) RAB9AL3MBTL1HTTNPSR1KMT2A
SCHEMBL20406301 0.79 AHR (0.46) KMT2AALDH1A1MEN1MAPT
SCHEMBL28014854 0.79 L3MBTL1 (0.58) RAB9AL3MBTL1HTTNPSR1KMT2A
SCHEMBL25307563 0.79 RAB9A (0.60) RAB9AL3MBTL1HTTKMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8198287-B2 Substituted heteroaryl pyridopyrimidone derivatives SANOFI-AVENTIS (FR) 2012-06-12 US disclosed
US-8198287-B2 Substituted heteroaryl pyridopyrimidone derivatives SANOFI-AVENTIS (FR) 2012-06-12 US disclosed
US-20090306088-A1 SUBSTITUTED HETEROARYL PYRIDOPYRIMIDONE DERIVATIVES SANOFI-AVENTIS (FR) 2009-12-10 US disclosed
US-20090306088-A1 SUBSTITUTED HETEROARYL PYRIDOPYRIMIDONE DERIVATIVES SANOFI-AVENTIS (FR) 2009-12-10 US disclosed
US-20080312435-A1 Imine Compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2008-12-18 US disclosed
US-20080312435-A1 Imine Compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2008-12-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312435-A1 Imine Compound CNR1, CNR2, HRH4 RAB9A 841/4885L3MBTL1 2504/4885HTT 945/4885
US-20090306088-A1 SUBSTITUTED HETEROARYL PYRIDOPYRIMIDONE DERIVATIVES GSK3B, GSK3A, GSKIP RAB9A 1519/4885L3MBTL1 2135/4885HTT 488/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.